RT Journal Article
SR Electronic
T1 Hyponatraemia and mortality in psychiatric patients: protocol for Bayesian causal inference study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.25.20138206
DO 10.1101/2020.06.25.20138206
A1 Kaas-Hansen, Benjamin Skov
A1 Graudal, Niels
A1 Andersen, Stig Ejdrup
A1 Thygesen, Lau Caspar
A1 Brunak, Søren
A1 Jürgens, Gesche
YR 2020
UL http://medrxiv.org/content/early/2020/06/30/2020.06.25.20138206.abstract
AB Introduction Hyponatriaemia has been associated with mortality in somatic patients, but little is known about the nature of such an association in psychiatric patients. This manuscript details a study to investigate if hyponatraemia be a direct contributor to death in schizophrenic and bipolar patients. It will further gauge the potential role of somatic comorbidity and psychotropic polypharmacy, with emphasis on antipsychotics and antidepressants.Methods Density sampled case-control study of schizophrenic and bipolar patients from the Capital Region and Region Zealand in Denmark using prospective data from Danish registries and electronic medical records. Cases deceased between 1 January 2011 and 1 July 2016; controls were found by risk-set sampling, matched by date of birth +/- 180 days. We will use a fully Bayesian, non-linear, conditional logistic regression model to estimate the causal effect of serum sodium level on death, with covariates selected by a causal diagram. Continuous covariates will be modelled with restricted (natural) cubic splines to elicit non-linear relationships. A sample of 10 cases and 50 controls was drawn to ascertain that the proposed study be sound and realistic.Conclusion This study will expand the body of evidence on the effect of hyponatriaemia on mortality in schizophrenic and bipolar patients and may guide clinical decision-making in terms of both monitoring intensity and rational use of psychotropics.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04409626Funding StatementThe study was funded by Innovation Fund Denmark (5153-00002B) and Novo Nordisk Foundation (NNF14CC0001).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data collection and linkage were approved by the Danish Health Data Authority (FSEID-00003724) and the Danish Patient Safety Authority (3-3013-1731-1).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe use sensitive data from national registries and electronic medical records. We cannot share these.